Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Dr Reddy’s launches oral semaglutide biosimilar Obeda for type 2 diabetes in India
Shares of Dr Reddy's Laboratories Ltd ended at ₹1,320.00, down by ₹13.95, or 1.05%, on the BSE.
Margin revival, Semaglutide launch to drive Dr Reddy’s growth momentum in FY27
Dr Reddy's Laboratories anticipates a gradual recovery this fiscal year. The company faced a profit drop last year due to US business pressures. However, operations in India, Europe, and emerging markets show healthy growth. New launches like Semaglutide and Abatacept are expected to drive future expansion. Margins are set to improve with better product mix and cost controls.
Dr Reddy's Laboratories shares volatile after an 86% YoY decline in Q4 profit. Should you buy?
Dr Reddy shares swung between gains and losses in morning deals on the BSE on Wednesday, 13 May. It rose nearly 3% and then plunged 4% during the session.
Dr Reddy's Laboratories Q4 Results: Cons PAT falls 86% YoY to Rs 221 crore, revenue dips 12%; Rs 8 per share dividend announced
Dr Reddy's Laboratories Q4 Results: Dr. Reddy's Laboratories reported a consolidated net profit at Rs 221 crore in the March-ended quarter versus Rs 1,587 crore in the year ago period, an 86% YoY fall.
Dr Reddy's Q4 results 2026: Profit plunges 86% YoY to ₹220 crore; board recommends a final dividend of ₹8
Dr Reddy's Q4 results 2026: Dr Reddy's Laboratories reported a sharp 86.2% YoY fall in its consolidated net profit to ₹220.1 crore for Q4FY26. The company's board recommended a final dividend of ₹8 per share of face value of ₹1 each for FY26.
Q4 Results LIVE Updates: Dr. Reddy's, Dixon report results today; Indian Hotels, Anant Raj react
Q4 Results LIVE Updates: Its an earnings-heavy day on the Dalal Street today. Nifty 50 stock Dr Reddy's Laboratories is scheduled to report its numbers today. Dixon Tech, Berger Paints, Nazara Tech, INOX India, Cohance Lifesciences, Gopal Snacks, Kalpataru, KPR Mill, Max Financial Services, MobiKwik, MTAR Tech, Novartis, Pfizer, Religare, Keystone Developers, Sagility, Tata Power, Torrent Power, Texmaco Rail, V-Guard Industries, are among the other important results to track today. Watch this space for all the LIVE earnings updates.
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories maintains a low beta value.
Market Trading Guide: Buy Dr Reddy’s Laboratories and Solar Industries on Friday for gains up to 14%
Nifty extended losses amid weakness in key sectors, facing resistance near moving averages. Analysts highlight a crucial trading range for direction while recommending select stocks showing bullish breakouts, strong momentum, and accumulation supported by rising volumes
Dr. Reddy's Laboratories still awaiting approval for a major near-term trigger, sources say
Analysts who track Dr. Reddy's expect six to nine months of no competition in the Canadian market and that the street is working with revenue between $80 million to $100 million in Canada for financial year 2027.
Dr Reddy's partner Immutep told to halt phase III trial of lung cancer drug eftilagimod alfa
Enrolment in the study is being halted in response to the Independent Data Monitoring Committee's recommendation. Shares of Dr Reddy's Laboratories Ltd ended at ₹1,288.40, down by ₹30.35, or 2.30%, on the BSE today, March 13.
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories sees a healthy return
Dr Reddy’s gets USFDA Establishment Inspection Report for Andhra's Srikakulam facility
Shares of Dr Reddy's Laboratories Ltd ended at ₹1,307.00, up by ₹15.85, or 1.23%, on the BSE.